baha the information company

baha is a leading provider of real-time market data, financial news, technology and solutions for the financial industry. baha offers real-time data terminals for professionals, global financial market data covering over 12 million financial instruments on more than 150 exchanges, as well as 24/7 breaking news with global coverage and free web and mobile apps. From a total of around 200 real-time data providers worldwide, only Reuters 1851, Bloomberg 1981 and now baha in 2021 were named after the founder.

UBS Knock-Out AMGN/ DE000UM2QF19 /

2024-07-31 2:52:08 PM	Chg.-0.01	Bid5:45:31 PM	Ask5:45:31 PM	Underlying	Strike price	Expiration date	Option type
1.13EUR	-0.88%	1.13 Bid Size: 50,000	1.14 Ask Size: 50,000	Amgen Inc	455.2173 USD	2078-12-31	Put

GlobeNewswire 07-01 Zenas BioPharma Appoints Orlando Oliveira as Chief Commercial Officer

GlobeNewswire 06-27 Eliem Therapeutics Announces the Closing of its Acquisition of Tenet Medicines and Concurrent $120 M...

GlobeNewswire 06-27 Coherus BioSciences Announces Divestiture of YUSIMRY (adalimumab-aqvh) in a $40 Million Upfront All ...

GlobeNewswire 06-26 COUR Pharmaceuticals Appoints Tim Walbert to its Board of Directors

GlobeNewswire 06-26 Compass Pathways appoints Lori Englebert as Chief Commercial Officer

GlobeNewswire 06-25 Arthritis Foundation Launches Carolina Hills Classic Bike Tour, Coming June 2025

TeleTrader 06-24 US closes mostly lower, as energy, banking stocks take lead

GlobeNewswire 06-20 Biotechs Race to Develop New Treatments as Global Pancreatic Cancer Market Size Expected to Reach $7...

GlobeNewswire 06-19 Jasper Therapeutics Announces Appointment of Svetlana Lucas Ph.D., to its Board of Directors

GlobeNewswire 06-18 CytomX Therapeutics to Present at the H.C. Wainwright 2nd Annual Immune Cell Engager Virtual Confere...

GlobeNewswire 06-17 CytomX Therapeutics Promotes Chris Ogden to Chief Financial Officer

GlobeNewswire 06-17 FDA Approves Phase II Clinical Trial for Ruxoprubart in ANCA Associated Vasculitis (AAV) – a Chronic...

GlobeNewswire 06-17 Solid Power Appoints Renewables Industry Veteran Linda Heller as Chief Financial Officer

GlobeNewswire 06-05 Coherus BioSciences Appoints Rita Karachun, CPA, CGMA to its Board of Directors

GlobeNewswire 05-30 Crinetics Pharmaceuticals Appoints Robert M. Cuddihy, M.D., as Senior Vice President of Medical Affa...

TeleTrader 05-28 US markets turn to losses, Dow plunges 330 points

TeleTrader 05-28 Wall Street opens mostly higher as T+1 stock trading returns

GlobeNewswire 05-28 Apogee Therapeutics Expands Board of Directors with the Appointment of Lisa Bollinger, MD

GlobeNewswire 05-27 Samsung Bioepis Announces Oral Presentation on Switching Period Results for SB16, a Proposed Biosimi...

GlobeNewswire 05-23 Coherus Presents Preliminary Results from Phase I Dose Escalation Study of its Anti-chemokine recept...

GlobeNewswire 05-22 CytomX Therapeutics to Present at the Jefferies Global Healthcare Conference

GlobeNewswire 05-22 Sandoz receives European Commission approval for Wyost® and Jubbonti®, the first and only biosimilar...

GlobeNewswire 05-21 Alvotech Reports Financial Results for First Quarter of 2024 and Provides a Business Update

GlobeNewswire 05-21 Alvotech and Dr. Reddy’s enter into collaboration for commercialization of AVT03 (denosumab), a bios...

GlobeNewswire 05-21 COUR Pharmaceuticals Appoints Paul M. Peloso, MD, as Chief Medical Officer

UBS Knock-Out AMGN/ DE000UM2QF19 /

If you wish to receive reply to your feedback, please provide your email address.